http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Eli Lilly & Co. (LLY) Acquire Versanis
-
Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases
-
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC
-
Eli Lilly (LLY) Announces NEJM Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
Eli Lilly & Co. (LLY) to Acquire Sigilon Therapeutics (SGTX) for $14.92/sh plus CVR
-
Lilly to Acquire Sigilon Therapeutics
-
Eli Lilly & Co. (LLY) Reports Publication of Phase 2 retatrutide Results
-
Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and
-
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes
-
Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks
-
Eli Lilly & Co. (LLY) Announces FDA Approval of Jardiance
-
US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older
-
Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions
-
Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch "Tap the Cap"
-
Eli Lilly & Co. (LLY) to Acquire DICE Therapeutics (DICE) for $48/sh or $2.4B
-
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
-
Eli Lilly & Co. (LLY) Says Head-to-Head Clinical Trial Reaffirms Efficacy of Emgality in Episodic Migraine Prevention, Study Misses Primary Endpoint
-
First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention
-
Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting
-
Lilly to Participate in Goldman Sachs Global Healthcare Conference
-
Lilly ESG Report Highlights Progress Towards Sustainability Goals
-
Eli Lilly & Co. (LLY) Announces Publication of peresolimab Phase 2a Rheumatoid Arthritis Trial
-
Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
-
Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
-
Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation
-
Eli Lilly & Co. (LLY) Reports Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program for Mirikizumab
-
Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis
-
Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
-
Eli Lilly & Co. (LLY) Reports Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands
-
Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis
-
Avidity Advances RNA Programs and Expands into New Therapeutic Areas Utilizing its AOC™ Platform
-
Lilly to Participate in Evercore ISI HealthCONx Conference
-
Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform
-
Bigfoot Biomedical Announces Insulin Compatibility Expansion to Support Insulin Affordability and Flexibility for People with Diabetes
-
Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease
-
Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting
-
Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration
-
Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement
-
Eli Lilly & Co. (LLY) Acquires Akouos (AKUS) for $610M
-
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
-
Eli Lilly & Co. (LLY) Granted FDA Fast Track designation for tirzepatide
-
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
-
Eli Lilly (LLY) Announces FDA Approval of Retevmo
-
FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type
-
Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials
-
Lilly Announces Details of Presentations at ESMO Congress 2022
-
Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
-
Lilly to Participate in Citi's 17th Annual BioPharma Conference
-
Eli Lilly & Co. (LLY) Announces Taltz Now Available in Citrate-Free Formulation
